Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Leukemia, Myeloid, Acute 5Ovarian Neoplasms 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

3-Iodobenzylguanidine 3cabozantinib 2tipifarnib 1pembrolizumab 1pazopanib 1lutetium Lu 177 dotatate 1lenvatinib 1guadecitabine 1fostamatinib 1copper dotatate CU-64 1atezolizumab 1Temozolomide 1Surgical Procedures, Operative 1Sunitinib 1Phenoxybenzamine 1Nivolumab 1Lutetium-177 1Lutetium 1Iodine-131 1Everolimus 1Erlotinib Hydrochloride 1Doxazosin 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pheochromocytoma × guadecitabine × Clear all
NCT03165721 2026-02-18

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
9 enrolled 11 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Kidney Neoplasms, Paraganglioma, Pheochromocytoma, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡